Skip to main content

Table 1 Baseline characteristics of patients between ganciclovir-treated and non-treated group

From: Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation

Variables

Ganciclovir treated

(n = 66)

Non-treated

(n = 70)

P value

Sex, male

47 (71.2)

40 (57.1)

0.088

Age (years)

71.5 (62.3–80.0)

69 (59.8–76.0)

0.419

Pneumonia

60 (90.9)

64 (91.4)

0.915

Severity variables

 ICU

29 (43.9)

17 (24.3)

0.015

 Mechanical ventilation

16 (24.2)

10 (14.3)

0.140

 Quick SOFA

1 (0.0–2.0)

1 (1.0–1.0)

0.650

 CWI

1 (1.0–2.0)

1 (0.0–1.3)

0.177

 HD > 30 days after CMV reactivation

42 (63.6)

31 (44.3)

0.024

 CMV PCR > 5000 copies/ml

32(48.5)

16 (22.9)

< 0.002

 CMV DNAemia duration (days)

12 (9.0–19.0)

8.5 (7.0–15.5)

0.137

 Progress to CMV pneumonitis

10 (15.2)

0 (0.0)

0.001

Endpoint

 30-months survival

14/50 (28)

21/54 (38.9)

0.240

 One-year survival

25/62 (40.3)

30/61 (49.2)

0.323

 90-days survival

47/63 (74.6)

60/69 (87)

0.070

 Cardiovascular events

4 (6.1)

2 (2.9)

0.363

  1. Data are expressed as number (%) of patients or median (IQR)
  2. Abbreviations: ICU intensive care unit, SOFA sequential organ failure assessment, CWI Charlson’s weighted index of comorbidity, HD hospital day CMV Cytomegalovirus, PCR polymerase chain reaction